Brentuximab vedotin inj
Products billed under this code include Adcetris.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Adcetris.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Adcetris | Pfizer Inc | 51144-0050-01 | 50 | $13,960.35 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $279.207 | $0.00 | 1 MG | Brentuximab vedotin inj | v1, posted September 17, 2026 |
| 3Q26 | $279.207 | +$10.48 | 1 MG | Brentuximab vedotin inj | v1, posted September 15, 2026 |
| 2Q26 | $268.727 | +$0.276 | 1 MG | Brentuximab vedotin inj | v1, posted September 15, 2026 |
| 1Q26 | $268.451 | +$9.811 | 1 MG | Brentuximab vedotin inj | v1, posted September 15, 2026 |
| 4Q25 | $258.64 | +$0.124 | 1 MG | Brentuximab vedotin inj | v1, posted September 8, 2026 |
| 3Q25 | $258.516 | +$9.586 | 1 MG | Brentuximab vedotin inj | v1, posted March 10, 2026 |
| 2Q25 | $248.93 | $0.00 | 1 MG | Brentuximab vedotin inj | v1, posted March 10, 2026 |
| 1Q25 | $248.93 | +$9.074 | 1 MG | Brentuximab vedotin inj | v1, posted December 19, 2025 |
| 4Q24 | $239.856 | +$0.254 | 1 MG | Brentuximab vedotin inj | v1, posted June 11, 2025 |
| 3Q24 | $239.602 | +$8.86 | 1 MG | Brentuximab vedotin inj | v1, posted June 11, 2025 |
| 2Q24 | $230.742 | +$0.128 | 1 MG | Brentuximab vedotin inj | v1, posted March 11, 2025 |
| 1Q24 | $230.614 | +$8.50 | 1 MG | Brentuximab vedotin inj | v1, posted December 19, 2024 |
| 4Q23 | $222.114 | +$0.15 | 1 MG | Brentuximab vedotin inj | v1, posted October 10, 2024 |
| 3Q23 | $221.964 | +$8.167 | 1 MG | Brentuximab vedotin inj | v1, posted June 5, 2024 |
| 2Q23 | $213.797 | +$0.143 | 1 MG | Brentuximab vedotin inj | v1, posted February 23, 2024 |
| 1Q23 | $213.654 | +$7.898 | 1 MG | Brentuximab vedotin inj | v1, posted December 6, 2023 |
| 4Q22 | $205.756 | +$0.192 | 1 MG | Brentuximab vedotin inj | v1, posted June 22, 2023 |
| 3Q22 | $205.564 | +$8.911 | 1 MG | Brentuximab vedotin inj | v1, posted June 9, 2023 |
| 2Q22 | $196.653 | +$0.106 | 1 MG | Brentuximab vedotin inj | v1, posted December 14, 2022 |
| 1Q22 | $196.547 | +$7.212 | 1 MG | Brentuximab vedotin inj | v1, posted June 8, 2022 |
| 4Q21 | $189.335 | +$0.171 | 1 MG | Brentuximab vedotin inj | v1, posted June 2, 2022 |
| 3Q21 | $189.164 | +$7.106 | 1 MG | Brentuximab vedotin inj | v1, posted June 2, 2022 |
| 2Q21 | $182.058 | −$0.022 | 1 MG | Brentuximab vedotin inj | v1, posted March 1, 2022 |
| 1Q21 | $182.08 | – | 1 MG | Brentuximab vedotin inj | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.